X
API Suppliers
US DMFs Filed
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
Chinook Therapeutics in-license of atrasentan provides a unique opportunity for Chinook to add a potential new drug to its precision medicine portfolio for the treatment of rare CKD conditions.
Lead Product(s): Atrasentan
Therapeutic Area: Nephrology Product Name: CHK-01
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Chinook Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement January 10, 2020
EMWA 2024
Not Confirmed
Contact SupplierDetails:
Novartis will acquire SanReno's pipeline and capabilities, including the exclusive rights for Greater China and Singapore for two late-stage assets targeting IgAN, ABT-627 (atrasentan), an oral ERA antagonist and zigakibart, a subcutaneously administered monoclonal antibody.
Lead Product(s): Atrasentan
Therapeutic Area: Nephrology Product Name: ABT-627
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Novartis Pharmaceuticals Corporation
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition January 05, 2024
Details:
CHK-01 (atrasentan hydrochloride) is an investigational oral endothelin A receptor antagonist (ERA), currently in Phase III development for IgAN and early-stage development for other rare kidney diseases
Lead Product(s): Atrasentan
Therapeutic Area: Nephrology Product Name: CHK-01
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 30, 2023
Details:
CHK-01 (atrasentan hydrochloride), an oral endothelin A receptor antagonist is being evaluated phase 3 clinical trials for proteinuria reduction in patients with IgA nephropathy.
Lead Product(s): Atrasentan
Therapeutic Area: Nephrology Product Name: CHK-01
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 30, 2023
Details:
Through the acquisition, Novartis expands its portfolio with chinook's renal pipeline having 2 assets, CHK-01 (atrasentan hydrochloride), an oral endothelin A receptor antagonist and BION-1301 (zigakibart), an anti-APRIL monoclonal antibody, for Immunoglobulin A Nephropathy.
Lead Product(s): Atrasentan
Therapeutic Area: Nephrology Product Name: CHK-01
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Novartis Pharmaceuticals Corporation
Deal Size: $3,500.0 million Upfront Cash: $3,500.0 million
Deal Type: Acquisition August 11, 2023
Details:
Through the acquisition, Novartis expands its portfolio with chinook's renal pipeline having 2 assets, CHK-01 (atrasentan hydrochloride), an oral endothelin A receptor antagonist and BION-1301 (zigakibart), an anti-APRIL monoclonal antibody, for Immunoglobulin A Nephropathy.
Lead Product(s): Atrasentan
Therapeutic Area: Nephrology Product Name: CHK-01
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Novartis Pharmaceuticals Corporation
Deal Size: $3,500.0 million Upfront Cash: $3,500.0 million
Deal Type: Acquisition June 12, 2023
Details:
Atrasentan (CHK-01), is a potent and selective endothelin A receptor antagonist that has the potential to provide benefit in multiple chronic kidney diseases by reducing proteinuria and having direct anti-inflammatory and anti-fibrotic effects to preserve kidney function.
Lead Product(s): Atrasentan
Therapeutic Area: Nephrology Product Name: CHK-01
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 03, 2022
Details:
Chinook intends to use the net proceeds from this offering to continue its phase 3 ALIGN and phase 2 AFFINITY trials of atrasentan, fund a phase 3 clinical trial of BION-1301, continue development of CHK-336 and prepare for the potential commercial launch of atrasentan.
Lead Product(s): Atrasentan
Therapeutic Area: Nephrology Product Name: CHK-01
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: SVB Securities
Deal Size: $105.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering May 25, 2022
Details:
CHK-01 (atrasentan) is a potent and selective inhibitor of the endothelin A receptor that has potential to provide benefit in multiple chronic kidney diseases by reducing proteinuria and having direct anti-inflammatory and anti-fibrotic effects to preserve kidney function.
Lead Product(s): Atrasentan
Therapeutic Area: Nephrology Product Name: CHK-01
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 20, 2022
Details:
Through this collaborative efforts with the IgA Nephropathy Foundation as well as the work at Chinook developing CHK-01 (atrasentan) and BION-1301 for IgA nephropathy, have learned that the patient journey can be daunting and isolating.
Lead Product(s): Atrasentan
Therapeutic Area: Nephrology Product Name: CHK-01
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Komodo Health
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration April 05, 2022
Details:
EC granted ODD to CHK-01(atrasentan), represents an important regulatory milestone that has the potential to expedite the global clinical development of atrasentan, a potent and selective ETA antagonist for the treatment of IGAN.
Lead Product(s): Atrasentan
Therapeutic Area: Nephrology Product Name: CHK-01
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 14, 2021
Details:
Chinook intends to use the net proceeds to advance the phase 3 ALIGN trial of atrasentan in patients with IgA nephropathy and the phase 2 AFFINITY basket trial of atrasentan in patients with proteinuric glomerular diseases, initiate clinical development of BION-1301 for IgAN.
Lead Product(s): Atrasentan
Therapeutic Area: Nephrology Product Name: CHK-01
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: SVB Leerink
Deal Size: $160.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering November 10, 2021
Details:
Atrasentan is a potent, selective endothelin A receptor (ETA) antagonist that has been evaluated in diabetic kidney disease patients in studies that demonstrated clinically significant and sustained reductions in proteinuria, as well as reduced risk of kidney function decline.
Lead Product(s): Atrasentan
Therapeutic Area: Immunology Product Name: ABT-627
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 22, 2020
Details:
Chinook will focus on advancing its product candidates for kidney disease, including, Planned Phase 3 and Phase 2 trials of atrasentan, going Phase 1b and future clinical trials of BION-1301, planned Phase 1 trial of CHK-336 and additional R&D programs related to CKD.
Lead Product(s): Atrasentan
Therapeutic Area: Immunology Product Name: ABT-627
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Chinook Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Merger October 05, 2020
Details:
Net proceeds will support company's planned phase 2 and phase 3 trials of atrasentan, an investigational selective endothelin receptor antagonist, in development for the treatment of IgA nephropathy and other primary glomerular diseases including other clinical activities.
Lead Product(s): Atrasentan
Therapeutic Area: Nephrology Product Name: ABT-627
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: EcoR1 Capital
Deal Size: $106.0 million Upfront Cash: Undisclosed
Deal Type: Private Placement August 18, 2020
Details:
Combined company will operate as chinook therapeutics and advance pipeline of clinical-stage programs in kidney diseases, led by Atrasentan and Bion-1301 in IGA nephropathy.
Lead Product(s): Atrasentan
Therapeutic Area: Nephrology Product Name: CHK-01
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Chinook Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Merger June 02, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
